Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$37.67M$37.67M+1.3% vs Q2 2025 Net Income-$5.49M-$5.49MN/M vs Q2 2025 EPS Diluted-$0.03-$0.03N/M vs Q2 2025 Gross Profit$26,094,000−4.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,213,000N/M Free Cash Flowderived-$2,351,000N/M Margins · derivedGross margin69.3%−4.2 pt vs Q2 2025
Operating margin-5.4%−1.0 pt vs Q2 2025
Net margin-14.6%−8.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end